Leukemia News

CancerConnect leukemia news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of leukemia research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of leukemia treatment and survivorship.

Share

Leukemia News


Hydrocortisone Significantly Improves Neuropsychological Issues in Some Children with Leukemia (May 16, 2016)

The use of physiologic doses of hydrocortisone appears to significantly improve neuropsychological issues caused by treatment including dexamethasone among children with acute lymphoblastic leukemia. These... Continue Reading

Advances in Blood Cancer Treatment (April 22, 2016)

Executive editor of CancerConnect and Women magazine oncologist Charles Weaver, MD describes highlights of current blood cancer research from 2015 and the American Society of Hematology (ASH) annual meeting. In... Continue Reading

Venclexta® Approved for Chronic Lymphocytic Leukemia (April 20, 2016)

The United States Food and Drug Administration (FDA) has approved the targeted agent, Venclexta® (venetoclax), for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a specific... Continue Reading

Vyxeos™ Improves Survival for Elderly in AML (March 30, 2016)

Results from a recent phase III clinical trial have demonstrated an improved survival benefit with the use of Vyxeos (CPX-351) compared with the standard chemotherapy combination consisting of cytarabine... Continue Reading

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant (March 30, 2016)

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio... Continue Reading

FDA Approves Imbruvica for First Line Treatment of Chronic Lymphocytic Leukemia (March 23, 2016)

Learn more about other FDA Approvals for CLL here. Find more information on CLL here. The US Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) for first-line use in patients with chronic... Continue Reading

Midostaurin Receives Breakthough Therapy Designation for Acute Myeloid Leukemia (March 16, 2016)

The targeted agent midostaurin (PKC412), which is still in investigative stages, has received “breakthrough therapy” designation by the United States Food and Drug Administration (FDA) for the treatment... Continue Reading

Arzerra® Approved as Maintenance Therapy for Advanced CLL (February 29, 2016)

The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already... Continue Reading

Advances in Leukemia: What do you need to know? (February 26, 2016)

The closing of 2015 made it increasingly clear that new discoveries in precision medicine and immunotherapy are leading to breakthrough therapies for a wide array of blood cancer patients. Chimeric antigen... Continue Reading

Crafting a Better T Cell for Immunotherapy (February 25, 2016)

New technology, not yet tested in humans, aims to reduce patients’ waiting time, increase potency of T-cell therapy T-cell therapy, a form of immunotherapy that uses a patient’s own immune cells to... Continue Reading

More Leukemia News

Latest Leukemia News By Stage


Screening/Prevention

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood cancers into focus, it’s time to increase public... Continue Reading

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (August 8, 2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod... Continue Reading

Link Between Allergies and Blood Cancers in Women (January 1, 2014)

Researchers have found a link between airborne allergies and the risk of blood cancers in women, according to the results of a study published in the American Journal of Hematology. Cancer research has increasingly become focused on the immune system... Continue Reading

Childhood CT Scans Linked to Leukemia and Brain Cancer Later in Life (June 20, 2012)

Children and young adults who undergo multiple computed tomography (CT) scans have an increased risk of leukemia and brain tumors in the decade following their first scan, according to the results of a study published in The Lancet. CT scans are a common... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

More Screening and Prevention

Chronic Lymphoblastic

Venclexta® Approved for Chronic Lymphocytic Leukemia (April 20, 2016)

The United States Food and Drug Administration (FDA) has approved the targeted agent, Venclexta® (venetoclax), for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a specific chromosomal abnormality, referred to as a 17p deletion.... Continue Reading

Arzerra® Approved as Maintenance Therapy for Advanced CLL (February 29, 2016)

The United States Food and Drug Administration (FDA) has approved Arzerra® (ofatumumab) as maintenance therapy for the treatment of advanced chronic lymphocytic leukemia (CLL). This product is already approved to treat patients with CLL who have not... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood cancers into focus, it’s time to increase public... Continue Reading

Gazyva/Chlorambucil Improves Outcomes in Older CLL Patients with Other Health Problems (December 16, 2013)

Among older people with chronic lymphocytic leukemia (CLL) and other health problems, initial treatment with Gazyva® (obinutuzumab) and chlorambucil was more effective than treatment with Rituxan® (rituximab) and chlorambucil. These results were presented... Continue Reading

More Chronic Lymphoblastic

Acute Lymphoblastic

Hydrocortisone Significantly Improves Neuropsychological Issues in Some Children with Leukemia (May 16, 2016)

The use of physiologic doses of hydrocortisone appears to significantly improve neuropsychological issues caused by treatment including dexamethasone among children with acute lymphoblastic leukemia. These results were published as an early release article... Continue Reading

Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (January 19, 2016)

Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH)... Continue Reading

Addition of Rituxan Improves Outcomes in Some Acute Lymphoblastic Leukemias (December 16, 2015)

The addition of Rituxan (rituximab) to standard chemotherapy-based regimens improves outcomes among patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) that is CD20-positive. These results were reported at a plenary session at the 2015... Continue Reading

Midostaurin Improves Survival in Subset of Acute Myeloid Leukemia (December 15, 2015)

The targeted agent, midostaurin, has demonstrated a survival improvement among patients with acute myeloid leukemia (AML) that has the TMS-like tyrosine kinase 3 (FLT3) mutation. These results were presented at a plenary session at the 2015 annual meeting... Continue Reading

More Acute Lymphoblastic

Acute Myeloid

Vyxeos™ Improves Survival for Elderly in AML (March 30, 2016)

Results from a recent phase III clinical trial have demonstrated an improved survival benefit with the use of Vyxeos (CPX-351) compared with the standard chemotherapy combination consisting of cytarabine and daunorubicin (7+3). These results will be submitted... Continue Reading

Midostaurin Receives Breakthough Therapy Designation for Acute Myeloid Leukemia (March 16, 2016)

The targeted agent midostaurin (PKC412), which is still in investigative stages, has received “breakthrough therapy” designation by the United States Food and Drug Administration (FDA) for the treatment of adults with acute myeloid leukemia. The breakthrough... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH)... Continue Reading

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant (December 30, 2015)

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since... Continue Reading

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

More Acute Myeloid

Acute Promyelocytic

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood cancers into focus, it’s time to increase public... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

September Is National Leukemia and Lymphoma Awareness Month (August 28, 2009)

As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated... Continue Reading

Arsenic Trioxide Effective as Single Agent in Newly Diagnosed APL (March 31, 2006)

Arsenic Trioxide Effective as Single Agent in Newly Diagnosed APL According to an article recently published in the journal Blood, the agent arsenic trioxide, when used as a single agent, provides impressive outcomes among patients with newly diagnosed... Continue Reading

More Acute Promyelocytic

Chronic Myeloid

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

Tasigna® Remains Superior to Gleevec® for Treatment of Newly Diagnosed Patients With Chronic Myeloid Leukemia (April 7, 2015)

Tasigna® (nilotinib) remains superior to Gleevec® (imatinib) for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (PH+CML), according to the results of the six-year update from the ENESTnd trial which were presented... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood cancers into focus, it’s time to increase public... Continue Reading

SYNRIBO® Approved for use in Chronic Myeloid Leukemia (February 21, 2014)

The U.S. Food and Drug Administration (FDA) has granted full approval of SYNRIBO® (omacetaxine mepesuccinate) for injection. SYNRIBO is indicated for adult patients with chronic phase (CP +0.28%, news) or accelerated phase (AP) chronic myeloid leukemia... Continue Reading

Iclusig Approved for CML and ALL (January 4, 2013)

The U.S. Food and Drug Administration (FDA) has approved Iclusig™ (ponatinib) to treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases. Chronic... Continue Reading

More Chronic Myeloid

Hairy Cell

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

Zelboraf® Appears Active in Hairy Cell Leukemia That Has Progressed After Other Treatment (October 7, 2015)

The medication Zelboraf® (vemurafenib) appears active in the treatment of hairy cell leukemia (HCL) that had progressed after previous therapy. These findings were published in New England Journal of Medicine. Hairy cell leukemia is a rare type of leukemia,... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood cancers into focus, it’s time to increase public... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

September Is National Leukemia and Lymphoma Awareness Month (August 28, 2009)

As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated... Continue Reading

More Hairy Cell

Adult Acute Lymphoblastic

Ask the Expert: Blood Cancer Treatment Progress & What’s Next (October 7, 2015)

CancerConnect Presents: Ask the Expert: Blood Cancer Treatment Progress & What’s Next In this informative web chat, Jacqueline Barrientos, MD discusses blood cancer prevalence, evolution of blood cancer treatments, the role of clinical trials... Continue Reading

Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia (October 10, 2014)

THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood cancers into focus, it’s time to increase public... Continue Reading

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment (July 21, 2014)

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

More Adult Acute Lymphoblastic

Childhood Acute Lymphoblastic

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood cancers into focus, it’s time to increase public... Continue Reading

One Subset of Childhood Acute Lymphoblastic Leukemia is Best Treated with Chemotherapy (April 20, 2012)

A subset of young patients with acute lymphoblastic leukemia (ALL) who fail to achieve remission after the initial weeks of intense chemotherapy known as induction therapy appear to have better outcomes with additional chemotherapy rather than bone marrow... Continue Reading

Many Patients with “Chemo Brain” Recover within Five Years (May 23, 2011)

A study of “chemo brain”—the foggy thinking and forgetfulness that patients may experience after chemotherapy—suggests that the condition improves substantially over time for a majority of patients. For some patients, however, symptoms may persist... Continue Reading

September Is National Leukemia and Lymphoma Awareness Month (August 28, 2009)

As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated... Continue Reading

Eliminating Preventive Radiation in Children with ALL (June 24, 2009)

Children with acute lymphoblastic leukemia (ALL) who are treated with effective, risk-adjusted chemotherapy regimens have good outcomes and may safely be able to avoid preventive radiation therapy to the brain. These results were published in the New... Continue Reading

More Childhood Acute Lymphoblastic

Chronic Lymphocytic

FDA Approves Imbruvica for First Line Treatment of Chronic Lymphocytic Leukemia (March 23, 2016)

Learn more about other FDA Approvals for CLL here. Find more information on CLL here. The US Food and Drug Administration (FDA) approved Imbruvica® (ibrutinib) for first-line use in patients with chronic lymphocytic leukemia (CLL). The approval means... Continue Reading

Promising Advances For Patients With Chronic Lymphocytic Leukemia (January 28, 2016)

Excerpted from: Advances in Cancer Research And Treatment: 2015 Year In Review A look at 10 of the most significant advances of the past year—progress that stands to benefit patients now and lays the foundation for future breakthroughs Patients with... Continue Reading

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings (December 31, 2015)

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH)... Continue Reading

ACP-196 Bruton’s Tyrosine Kinase Inhibitor Safe and Effective for Chronic Lymphocytic Leukemia (December 18, 2015)

Clinical results published in the New England Journal of Medicine show that the new drug acalabrutinib (ACP-196) is well tolerated and yields high response rates that are durable in patients with chronic lymphocytic leukemia (CLL). CLL is characterized... Continue Reading

Zydelig® Combined with Treanda and Rituxan Appears Promising in Treatment of Chronic Lymphocytic Leukemia (November 18, 2015)

Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc today announced that its Phase 3 clinical study evaluating Zydelig® (idelalisib) added to standard therapy in previously-treated chronic lymphocytic... Continue Reading

More Chronic Lymphocytic

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS